Asthma: key endpoint results by drug

The key endpoints of Asthma trials, with each approved or late-stage drug's result from its own trial: the lead dose against placebo (or the trial's active comparator), the week, and the arm size. These are the same rows as the drug comparison, for every drug at once. To set chosen drugs side by side, with every shared endpoint, use the comparison. The drug list and pipeline are on the Asthma page.

Severe exacerbations, annualised rate

Severe exacerbations, annualised rate in Asthma: 10 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
albuterol / budesonide0.50.6 (AS MDI)—80/180 μg · n 1054NCT03769090 Phase 3, secondary
Benralizumab0.91.9−0.9wk 24 · n 427NCT03170271 Phase 3, primary
Budesonide/glycopyrrolate/formoterol fumarate0.50.6 (budesonide/formoterol fumarate)—320/14.4/9.6 μg BID · wk 52 · n 725NCT04609878 Phase 3, primary
Depemokimab0.61.1−0.5wk 52 · n 252NCT04718103 Phase 3, primary
dupilumab0.51.0−0.4300 mg q2w · wk 52 · n 633NCT02414854 Phase 3, primary
Fluticasone propionate/salmeterol (Advair HFA)1.92.1 (Fluticasone Propionate)—250/50 mcg BID · wk 52 · n 306NCT00452699 Phase 4, secondary
Mepolizumab0.51.3−0.9100 mg · wk 52 · n 149NCT03562195 Phase 3, primary
risankizumab1.61.4+0.2wk 24 · n 105NCT02443298 Phase 2, secondary
tezepelumab0.92.1−1.2210mg Q4W · wk 52 · n 528NCT03347279 Phase 3, secondary
tralokinumab0.60.6±0300 mg Q2W · wk 52 · n 398NCT02161757 Phase 3, primary

Drugs checked with no result here: 36 not reported, 15 not posted, 12 trial running.

Trough FEV1, change

Trough FEV1, change in Asthma: 19 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
albuterol (Ventolin)0.10.0 (ADVAIR DISKUS)—200 mcg · wk 26 · n 120NCT02175771 Phase 3, secondary
albuterol / budesonide0.10.0+0.1160/180 μg · wk 12 · n 197NCT03847896 Phase 3, primary
Beclomethasone dipropionate/formoterol fumarate0.20.1 (CHF 718 pMDI)—800/24 µg total daily dose · wk 12 · n 274NCT05292586 Phase 3, secondary
Benralizumab0.40.2+0.130 mg q.4 Weeks · wk 48 · n 236NCT01928771 Phase 3, secondary
Budesonide / formoterol fumarate (SYMBICORT)0.20.1 (Budesonide)—wk 12 · n 150NCT00702325 Phase 4, primary
Budesonide/glycopyrrolate/formoterol fumarate0.10.1 (budesonide/formoterol fumarate)—320/14.4/9.6 μg BID · wk 24 · n 330NCT04609878 Phase 3, secondary
Depemokimab0.20.2+0.1wk 52 · n 239NCT04718103 Phase 3, secondary
dupilumab0.10.5−0.3wk 24 · n 13NCT03560466 Phase 3, secondary
Fluticasone Furoate0.20.0+0.1100 µg OD · wk 24 · n 111NCT01159912 Phase 3, primary
fluticasone furoate/umeclidinium/vilanterol0.10.1 (FF/VI)—100/31.25/25 mcg · wk 24 · n 399NCT02924688 Phase 3, primary
fluticasone furoate/vilanterol0.40.2+0.2100/25 µg OD · wk 12 · n 200NCT01165138 Phase 3, primary
Fluticasone propionate/salmeterol (Advair Diskus)0.10.1 (FF/VI)—100/31.25/25 mcg · wk 24 · n 399NCT02924688 Phase 3, primary
Glycopyrronium (PT001)0.10.1±028.8 μg · wk 24 · n 196NCT03358147 Phase 2/3, secondary
indacaterol maleate / mometasone furoate0.1-0.1+0.2wk 0.14 · n 36NCT00557440 Phase 2, primary
Olodaterol0.10.0+0.120 mcg qd · wk 4 · n 61NCT00467740 Phase 2, primary
risankizumab-0.1-0.0±0wk 24 · n 105NCT02443298 Phase 2, secondary
Tiotropium bromide0.1-0.0+0.22.5 mcg once daily · wk 24 · n 247NCT01172808 Phase 3, primary
Umeclidinium0.30.1+0.231.25 mcg QD · wk 24 · n 136NCT03012061 Phase 2, primary
Vilanterol0.30.1+0.125 µg · wk 4 · n 99NCT00600171 Phase 2, primary

Drugs checked with no result here: 34 not reported, 13 not posted, 7 trial running.

ACQ-5, change

ACQ-5, change in Asthma: 6 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Benralizumab0.20.1 (benralizumab)—wk 32 · n 112NCT04159519 Phase 4, secondary
Depemokimab-0.8-0.7−0.1wk 52 · n 246NCT04718103 Phase 3, secondary
dupilumab-1.4-1.1−0.3300 mg q2w · wk 12 · n 633NCT02414854 Phase 3, secondary
fluticasone furoate/vilanterol-1.2-1.1 (FF)—wk 24 · n 385NCT03248128 Phase 3, secondary
Glycopyrronium (PT001)-0.9-0.9+0.128.8 μg · wk 24 · n 195NCT03358147 Phase 2/3, secondary
Mepolizumab-0.8-0.4−0.4100 mg · wk 24 · n 266NCT02281318 Phase 3, secondary

Drugs checked with no result here: 38 not reported, 18 not posted, 11 trial running.

OCS dose reduction

OCS dose reduction in Asthma: 4 drugs, each from its own trial
DrugResultControlDifferenceDose · week · nTrial
Benralizumab75%25%+5030 mg q.4 Weeks · wk 28 · n 72NCT02075255 Phase 3, primary
dupilumab70.1%41.9%+28.2300 mg q2w · wk 24 · n 103NCT02528214 Phase 3, primary
Mepolizumab-50%0%−50100 mg SC · wk 24 · n 69NCT01691508 Phase 3, secondary
tralokinumab-37.6%-29.9%−7.8wk 40 · n 70NCT02281357 Phase 3, primary

Drugs checked with no result here: 38 not reported, 18 not posted, 13 trial running.

  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. Rows are in drug-name order, not ranked. Difference is the lead arm minus placebo, in the endpoint's unit. 73 approved or late-stage drugs with a featured trial in Asthma were checked; results come from ClinicalTrials.gov posted results unless marked. Updated 2026-11-20. How results are chosen: methodology.